Wave Life Sciences Ltd (NASDAQ:WVE) Director Gregory L. Verdine sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $38.86, for a total transaction of $582,900.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Wave Life Sciences stock opened at $40.25 on Monday. Wave Life Sciences Ltd has a 52-week low of $29.60 and a 52-week high of $56.00. The firm has a market capitalization of $1.19 billion, a PE ratio of -10.45 and a beta of 1.10. The company has a quick ratio of 6.11, a current ratio of 1.85 and a debt-to-equity ratio of 0.08.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Friday, November 9th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.02). Wave Life Sciences had a negative return on equity of 112.13% and a negative net margin of 1,114.49%. The business had revenue of $4.49 million during the quarter, compared to analyst estimates of $5.36 million. Research analysts anticipate that Wave Life Sciences Ltd will post -5 EPS for the current fiscal year.

Several equities analysts recently commented on the stock. Leerink Swann reaffirmed an “outperform” rating on shares of Wave Life Sciences in a research report on Sunday, November 11th. BidaskClub lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright set a $49.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a research report on Monday, November 12th. Mizuho set a $65.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, Stifel Nicolaus began coverage on shares of Wave Life Sciences in a research report on Monday, August 6th. They issued a “buy” rating and a $56.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Wave Life Sciences currently has a consensus rating of “Buy” and an average target price of $58.40.

Several institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its position in shares of Wave Life Sciences by 22.2% in the third quarter. Teachers Advisors LLC now owns 35,497 shares of the company’s stock worth $1,775,000 after acquiring an additional 6,453 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Wave Life Sciences by 27.1% in the third quarter. AQR Capital Management LLC now owns 13,828 shares of the company’s stock worth $691,000 after acquiring an additional 2,946 shares in the last quarter. Putnam Investments LLC acquired a new stake in shares of Wave Life Sciences in the third quarter worth $207,000. Point72 Asset Management L.P. increased its position in shares of Wave Life Sciences by 14.3% in the third quarter. Point72 Asset Management L.P. now owns 400,000 shares of the company’s stock worth $20,000,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Redmile Group LLC increased its position in shares of Wave Life Sciences by 1.3% in the third quarter. Redmile Group LLC now owns 2,273,307 shares of the company’s stock worth $113,665,000 after acquiring an additional 28,800 shares in the last quarter. 83.46% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/11/19/wave-life-sciences-ltd-wve-director-sells-582900-00-in-stock.html.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Story: What is a Futures Contract?

Insider Buying and Selling by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.